Nontyphoidal salmonella, a foodborne pathogen, causes human gastroenteritis worldwide. Among \>2,500 different *Salmonella enterica* serotypes, *Salmonella* Enteritidis and *Salmonella* Typhimurium are the most common serotypes responsible for human salmonellosis ([@R1]). In Europe, *Salmonella* Virchow has recently increased in prevalence, and a high proportion of isolated strains are resistant to multiple antimicrobial drugs ([@R2]--[@R4]).

Third-generation cephalosporins are widely used to treat major bacterial infections in humans and animals ([@R5]). However, the emergence and rapid spread of drug-resistant bacteria has become a serious public health concern. Extended-spectrum β-lactamases (ESBLs) are known to confer antimicrobial drug resistance by hydrolyzing most β-lactam antimicrobial drugs, including third-generation cephalosporins ([@R5]). Since the first report from Spain in 2000 of strains producing CTX-M-9 ([@R6]), which confers resistance to cefotaxime, various CTX-M--type ESBLs have been identified in *Salmonella* Virchow. In Spain, Belgium, and France, CTX-M-9 and CTX-M-2 producers spread clonally in humans and poultry ([@R7],[@R8]). In addition, the *bla*~CTX-M-15~ gene was identified in porcine isolates in South Korea ([@R9]). These reports demonstrate that CTX-M--producing *Salmonella* Virchow clones can be easily transmitted to humans through food products of animal origin. In South Korea, the incidence of *Salmonella* Virchow infections in humans has increased over the years, necessitating a nationwide survey of antimicrobial drug resistance in *Salmonella* Virchow isolates.

The Study
=========

During 2005--2014 in South Korea, local public health laboratories participating in the national surveillance network isolated 68 *Salmonella* Virchow strains from feces samples from patients with acute diarrhea. Until 2010, \<5 *Salmonella* Virchow strains were isolated per year, but this number gradually increased to 17 in 2014 ([Figure](#F1){ref-type="fig"}). *Salmonella* Virchow consistently ranked among the top 10 serotypes in prevalence during each study year in South Korea, accounting for ≈1.5%--2% of salmonellosis cases.
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We used the broth microdilution method ([@R10]) to perform antimicrobial susceptibility testing of *Salmonella* Virchow; results showed that 54 (79.4%) of the 68 isolates were resistant to [\>]{.ul}1 of the 15 antimicrobial agents tested ([Table](#T1){ref-type="table"}; [Technical Appendix](#SD1){ref-type="local-data"} Figure). The highest resistance rates were noted for nalidixic acid (77.9%), followed by ampicillin (44.1%), cefotaxime (44.1%), tetracycline (42.6%), and gentamicin (23.5%). Only 2 (2.9%) isolates were resistant to ciprofloxacin, but 50 (73.5%) had intermediate resistance. All of the isolates were susceptible to chloramphenicol, amikacin, or imipenem. Multidrug resistance, defined as resistance to at least 3 different classes of antimicrobial agents, was found in 30 (44.1%) isolates ([Table](#T1){ref-type="table"}).

###### Antimicrobial resistance profiles of *Salmonella enterica* serotype Virchow isolates in South Korea, 2005--2014\*

  Isolate no.   Antimicrobial drug                       No. resistant isolates
  ------------- ---------------------------------------- ------------------------
  1             --                                       14
  2             NAL                                      18
  3             TCY                                      2
  4             NAL, SXT                                 2
  5             TCY, NAL                                 2
  6             AMP, CEF, CTX, NAL                       5
  7             AMP, CEF, CTX, NAL, TCY                  7
  8             AMP, CEF, CTX, GEN, NAL                  1
  9             AMP, CEF, CTX, GEN, NAL, TCY             15
  10            AMC, AMP, CEF, CTX, FOX, SAM, NAL        1
  11            AMC, AMP, CEF, CTX, FOX, SAM, NAL, TCY   1
  Total                                                  68

\*AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CEF, cephalothin; CTX, cefotaxime; FOX, cefoxitin; GEN, gentamicin; NAL, nalidixic acid; SAM, ampicillin/sulbactam; SXT, trimethoprim/sulfamethoxazole; TCY, tetracycline; --, pansusceptible.

All multidrug-resistant isolates showed resistance to third-generation cephalosporins. In South Korea, cefotaxime-resistant strains were first isolated in 2011. Since then, 4, 9, and 14 isolates were collected in 2012, 2013, and 2014, respectively ([Figure](#F1){ref-type="fig"}). The rates of cefotaxime resistance in *Salmonella* Virchow have increased markedly, from 21.4% in 2011 to 82.3% in 2014. This annual trend of increasing cefotaxime resistance in South Korea is of interest because the rates were substantially higher than those reported in Spain during 2002--2006 (15%) ([@R11]) and Belgium during 2009--2013 (\<10%) ([@R12]). Moreover, even in Israel and Switzerland, where the incidence of *Salmonella* Virchow was relatively higher than that in South Korea, antimicrobial drug resistance to third-generation cephalosporins was rare ([@R3],[@R4]).

Among the 30 cefotaxime-resistant *Salmonella* Virchow isolates, 28 were confirmed to be ESBL-producers. PCR and sequencing of β-lactamase genes ([@R13]) confirmed that these 28 isolates harbored a *bla*~CTX-M-15~ gene, whereas the other 2 contained a *bla*~CMY-2~ gene. Cefotaxime resistance was transferred by conjugation from 9 *Salmonella* Virchow isolates to *Escherichia coli* J53 recipients, and the *bla*~CTX-M-15~ gene was identified in transconjugants. Southern blotting and PCR-based replicon typing ([@R14]) showed that all plasmids in transconjugants were ≈215 kb in size and possessed an IncHI2 plasmid, which was further assigned to sequence type (ST) 2 by plasmid double locus sequence typing ([@R15]). The analysis of the genetic environment surrounding the *bla*~CTX-M-15~ gene ([@R13]) in transconjugants showed that insertion sequences IS*Ecp1* and o*rf477* were detected 48 bp upstream and downstream of the *bla*~CTX-M-15~ gene, respectively. This IS*Ecp1*-*bla*~CTX-M-15~--open reading frame 477 transposable unit was also identified in other incompatibility groups of the plasmids in *Enterobacteriaceae*. Furthermore, it was identical to that of the ST2-IncHI2 plasmid of *Salmonella* Enteritidis isolated from humans and poultry meat in South Korea (J. Kim, unpub. data), suggesting that the *bla*~CTX-M-15~ gene in *Salmonella* Virchow might have originated from IS*Ecp1*-mediated transposition followed by interspecies spread through the IncHI2-type plasmid studied here.

All of the CTX-M-15--producing strains had reduced ciprofloxacin susceptibility (MICs of 0.25--0.5 µg/mL). All 10 randomly selected isolates harbored a single substitution within the quinolone resistance--determining region of GyrA at codon 83 (Ser→Phe), which is the major mutation described in *Salmonella* species ([@R8]). Because fluoroquinolones and third-generation cephalosporins are the drugs of choice for treating severe *salmonella* infections in humans, the reduced ciprofloxacin susceptibility in cefotaxime-resistant *Salmonella* Virchow is considered a critical risk factor for infections with these strains.

The genetic relationship of the 68 *Salmonella* Virchow isolates was determined by using multilocus sequence typing (<http://mlst.warwick.ac.uk/mlst/dbs/Senterica>) and pulsed-field gel electrophoresis (PFGE) according to a standardized protocol. Seven multilocus sequence typing loci displayed 4 different profiles, and most isolates belonged to sequence type (ST) 16 (n = 59), followed by ST197 (n = 6), ST359 (n = 2), and ST426 (n = 1). All of the 28 CTX-M-15--producing strains were typed as ST16, but the cefotaxime-susceptible isolates were also assigned to this type. The PFGE analysis yielded sufficient discriminatory power in typing *Salmonella* Virchow isolates; 22 *Xba*I and 21 *Bln*I PFGE patterns were generated. Although the isolates shared [\>]{.ul}70% similarity, CTX-M-15--producing strains clustered on the basis of a similarity value of 90% ([Technical Appendix](#SD1){ref-type="local-data"} Figure), indicating the clonality of cefotaxime-resistant strains.

For humans, the main route of *Salmonella* infection is the consumption of contaminated food of animal origin, and *Salmonella* Virchow is one of the most prevalent serotypes identified in poultry and poultry products. The use of cephalosporins in animal production has led to emergence of antimicrobial drug--resistant *Salmonella* Virchow clones among food animals ([@R8]), posing a threat to public health because of the possible transmission of these bacteria through the food chain. In fact, the *Xba*I PFGE pattern identified among human isolates in this study was identical to that in 2 cefotaxime-resistant *Salmonella* Virchow strains isolated in 2012 from poultry meat in our collection ([Technical Appendix](#SD1){ref-type="local-data"} Figure). Furthermore, this pattern appeared similar to the patterns of *Salmonella* Virchow harboring the *bla*~CTX-M-15~ gene on an ST2-IncHI2 plasmid that was isolated from organically raised pigs in South Korea ([@R9]). Resistant clinical strains were collected from 13 of 15 local public health laboratories in South Korea during 2011--2014; thus, although the mode of the spread of *Salmonella* Virchow in humans is not established, it has been postulated that CTX-M-15--producing *Salmonella* Virchow might have disseminated clonally through the nationwide distribution of contaminated food products rather than through independent emergence.

Conclusions
===========

We analyzed the antimicrobial drug susceptibility and genetic relatedness of *Salmonella* Virchow isolates from patients with diarrhea in South Korea. Of 68 isolates obtained during 2005--2014, a total of 30 were resistant to third-generation cephalosporins. The prevalence rate of the resistant strains has dramatically increased since the isolation of cefotaxime-resistant strains in 2011. These findings suggest that the cefotaxime-resistant isolates are genetically closely related and harbor a plasmid carrying the *bla*~CTX-M-15~ gene of the same compatibility group (ST2-IncHI2), representing clonal dissemination of CTX-M-15--producing *Salmonella* Virchow in South Korea and posing an urgent threat to public health. Therefore, more comprehensive surveillance is required to prevent further spread of resistant clonal strains.

###### Technical Appendix

Composite dendrogram of the genetic relatedness among *Salmonella enterica* serotype Virchow isolates in Republic of Korea.
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